Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;100(2):197-213.
doi: 10.1007/s00109-021-02162-3. Epub 2021 Nov 20.

Circulating tumor cells in colorectal cancer in the era of precision medicine

Mingchao Hu  1   2   3 , Zhili Wang  2 , Zeen Wu  1   2 , Pi Ding  2 , Renjun Pei  4 , Qiang Wang  5 , Chungen Xing  6
Affiliations
Review

Circulating tumor cells in colorectal cancer in the era of precision medicine

Mingchao Hu et al. J Mol Med (Berl). 2022 Feb.

Abstract

Colorectal cancer (CRC) is one of the main causes of cancer-related morbidity and mortality across the globe. Although serum biomarkers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA-199) have been prevalently used as biomarkers in various cancers, they are neither very sensitive nor highly specific. Repeated tissue biopsies at different times of the disease can be uncomfortable for cancer patients. Additionally, the existence of tumor heterogeneity and the results of local biopsy provide limited information about the overall tumor biology. Against this backdrop, it is necessary to look for reliable and noninvasive biomarkers of CRC. Circulating tumor cells (CTCs), which depart from a primary tumor, enter the bloodstream, and imitate metastasis, have a great potential for precision medicine in patients with CRC. Various efficient CTC isolation platforms have been developed to capture and identify CTCs. The count of CTCs, as well as their biological characteristics and genomic heterogeneity, can be used for the early diagnosis, prognosis, and prediction of treatment response in CRC. This study reviewed the existing CTC isolation techniques and their applications in the clinical diagnosis and treatment of CRC. The study also presented their limitations and provided future research directions.

Keywords: Biomarkers; Circulating tumor cells; Colorectal cancer; Precision medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Global Burden of Disease Cancer C. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019 doi: 10.1001/jamaoncol.2019.2996. - DOI - PMC - PubMed
    1. Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, George S, Mant D. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311(3):263–270. doi: 10.1001/jama.2013.285718. - DOI - PubMed
    1. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19–9 and CA 72–4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 2002;22(4):2311–2316. - PubMed
    1. Khattak A. Liquid biopsies: advancing cancer research through drops of blood. Intern Med J. 2016;46(3):376–377. doi: 10.1111/imj.12996. - DOI - PubMed

Publication types

Substances